Introduction
The article by Guerin et al. [1] from Sarah Robertson's group in this issue of Biology of Reproduction reports a major advance in our understanding of the mechanism(s) by which male semen may protect the implanting semiallogeneic embryo against rejection by maternal innate and adaptive immune defenses. BALB/c (H-2 d ) males were used with C56BL6 (H-2 b ) females. Following mating, the lymph nodes draining the uterus (draining lymph nodes, DLN, or para-aortic lymph nodes, PALN) enlarge; this enlargement is greater when the male is allogeneic, that is, histoincompatible with the female, and generation of antipaternal cytotoxic T cells is suppressed [2] . The sequence of events is depicted in Figure 1 . Seminal plasma (SP) and spermatozoa (S) ejaculated into the uterine lumen at the time of mating on Gestation Day 0 (GD 0) act on the uterine epithelium, subendothelial macrophages (Mphs), and dendritic cells (DCs). This leads to the trafficking of cells (and perhaps of the predominant chemokine CCL19) via afferent lymphatics to para-aortic lymph nodes draining the uterus (DLN or PALN). There, CCL19 recruits circulating regulatory T cells (Tregs), identified by the presence of FOXP3, acting via the CCR7 receptor (and possibly CCR5). DCs may present antigens from SP (blue dots) or S (red dots). Activated Treg cells exit the lymph nodes and home to the uterine lining by GD 3.5, again mediated for the most part by CCL19 binding to CCR7. Interestingly, measuring mRNA for Foxp3 showed an increase that was reduced by about half if SVX males lacking SP or VAS males lacking S were used, suggesting that S could activate Foxp3 þ mRNA in uterine cells without significantly increasing CCL19-dependent Treg cell recruitment, although both S plus SP were required for maximal activation. On GD 4.5, the semiallogeneic blastocyst, potentially susceptible to rejection directed against minor paternal histocompatibility antigens [2] , implants itself. Guerin et al. [1] argue that the regional generation and local recruitment of Treg cells to the uterus in advance of implantation acts to protect the implanting embryo against maternal immune rejection. In support of this contention, they noted an increase in CD4 þ CD25 þ cells in the DLN that did not express FOXP3, which could represent activated effector T cells.
Why Is This Important?
The ability of maternal T cells to reject the implanted semiallogeneic embryo was first suggested by Munn et al. [5] and Mellor et al. [6] who reported that infusing racemic 1-methyltryptophan to block the tryptophan-degrading indoleamine-deoxygenase enzymes (IDO-1 and IDO-2) led to infiltration of the uterus by CD4 þ T cells, deposition of complement component C3, and an inflammatory destruction of semiallogeneic (but not syngeneic) embryos. This rejection began shortly after implantation and concluded before the usual time of onset of the resorption/abortion process in the CBAxDBA/2 model (i.e., GD 9.5). 1-MT-induced embryo failure, where maternal cytotoxic T cells (CTLs) kill alloantigen-bearing cells of the putative allograft, is an indirect rejection. In indirect rejection, foreign paternal antigens are taken up by antigen-presenting cells such as maternal DCs and Mphs in the uterine lining and are processed into peptides that bind to the groove of maternal major histocompatibility complex (MHC) Class Ia and Class II molecules on the surface of DCs and Mphs. These so-called professional antigen-presenting cells (APCs) can then bind to ab-type T cell receptors (TcRs) on maternal T cells, and this interaction is prolonged long enough for T cell activation by CD8 on T cells binding to Class I MHC on the APCs or by CD4 binding to Class II MH on the APCs. T cells that are CD4 þ 8 þ can bind to either Class I MHC or Class II MHC. The antigen-activated T cells then receive a second signal from the APCs, allowing them to develop into CTLs or into T helper (Th) cells that release proinflammatory cytokines such as tumor necrosis factor-a. In the process of indirect rejection, cytokineproducing Th cells play the major role. More recently Aluvihare et al. [7] showed that pregnant immunodeficient females restored with syngeneic CD4 þ T cells, from which CD4 þ CD25 þ Treg cells had been removed, experienced failure of allogeneic, but not syngeneic, embryos. Most of the failures occurred soon after implantation, but a few embryos survived long enough to be seen as classical resorptions (abortions). Again, rejection was mediated by ab TcR þ effector T cells. This was surprising because the implanted semiallogeneic conceptus within its trophoblastic cocoon has been known for more than 50 years to be resistant to rejection by transplantation immunity mediated by ab TcR þ T cells [2] . These two models were artificial, but recently Kahn and Baltimore [8] have shown that blocking Treg cells by a method other than administration of monoclonal anti-IL2RA (CD25), which can activate T cells, led to selective loss of embryos bearing the male H-Y minor histocompatibility antigen. Treg cells in DLN can account for failure of embryonic paternal alloantigens to stimulate transplantation immunity, and locally within the uterus, Treg cells can prevent maintenance of the activation of effector T cells required for rejection. A similar inability to maintain activated effector T cells has been suggested to explain the inefficacy of antitumor immunity against an established tumor [9, 10] . Such a mechanism can explain why transplantation immunity has never been able to cause embryo rejection: immunity to embryo-associated paternal antigens cannot be expressed at the fetomaternal interface where indirect antigen presentation is the only effective mechanism of T cell activation.
A natural model of defective Treg cell activation causing embryo rejection is provided by the CBAxDBA/2 model [2] . Here, embryo failure does not begin until GD 9.5, and starting by GD 6.5, there is infiltration by maternal T cells that contain Vc1.1d6.3 TcR, which recognizes a non-species-specific trophoblast antigen [2, 11, 12] . It appears that NKT cells with this TcR-originally shown to be important in preventing abortions by the injection of antibody to the NK cell surface marker asialoGM1-initiate the Th1 cytokine response that leads to a proclivity for recurrent spontaneous abortion; NK cells also contribute [2, 11, 12] . Activation of NKcdT and NK cells is attenuated in part by the concomitant generation of Vc1.1d6.3 TcR þ cells that release a TGFB-like molecule, but the recruitment and activation of all of these cells appears to be abrogated if there is an adequate generation of ab TcR þ Treg cells prior to implantation [2, 11, 12] . A key question is the identity of the paternal antigens recognized by the Treg cells.
Moldenhauer et al. [13] have previously reported that uterine DCs can take up and present minor antigens present in SP. Therefore, recruiting Treg cells to where DCs are located with such antigens could activate inflammation-producing ab TCR þ effector T cells, and this would tip the balance toward nonrejection. This has been described as maternal tolerance of a fetal allograft, but unlike transplantation tolerance, as seen with organ allografts, the tolerance process in pregnancy is localized to the uterus. In the CBAxDBA/2 model, DBA/2 ejaculate is unable to generate an adequate Treg response, whereas BALB/c (also H-2 d ) can, and adoptive transfer of splenic Treg cells (CD4 þ CD25 þ ) to DBA/2-mated CBA/J females abrogates subsequent abortions provided the transfer is done by GD 2.5, but not if it is delayed until GD 4.5 [12, 14] . Indeed, even before implantation, Arck et al. [12] and Girardi et al. [15] have detected the beginning of a proinflammatory state in abortion-prone CBAxDBA/2 matings by GD 3.5. These observations are consistent with the idea that activation of Treg cells must occur in the DLN prior to implantation in order to provide enough time for Treg cells to traffic to the uterus and act prior to implantation. Interestingly, a protective Treg response to DBA/2 ejaculate can be achieved by injection Step 1, ejaculate from the allogeneic male enters the uterus, and between the moment of ejaculation, Gestation Day (GD) 0, and GD 2.5, antigens in seminal plasma (SP) and/or spermatozoa (S) act on epithelial cells lining the uterus, subepithelial maternal macrophages (Mphs), and dendritic cells (DCs). The processional antigen-presenting cells, Mph and DC, can leave the uterine lining and travel via the lymphatics to para-aortic lymph nodes draining the uterus (DLN). The locally released chemokine arising from the epithelium and APC may also travel via the lymphatics to the DLN. However, only SP, but not S, induces CCL19. In Step 2, SP-activated Mphs and DCs produce the chemokine CCL19, which recruits and retains Treg cells circulating in maternal blood. CCL19 acts primarily via the chemokine receptor CCR7 on Treg cells. Antigen-activated Treg cells leave the DLN via the efferent lymphatics and enter the circulation. The promiscuous chemokine receptor CCR5 and other chemokines such as CCL3, CCL4, and CCL5 may also be involved (not illustrated) [3, 4] . CCL4 and CCR5 play a role in hormonedependent local recruitment of Treg cells to the uterus, which peaks at estrus (GD 0) just prior to mating [4] . This recruitment continues if pregnancy has been induced by allogeneic ejaculate, but locally produced CCL19 acting on CCR7 bound to circulating Treg cells also plays a major role in augmenting Treg cell numbers in the uterus as illustrated in Step 3 [1] . Spermatazoa can activate Treg cells, indicated by increased Foxp3, but does not augment/recruit Treg cells to the uterus because CCL19 is not induced [1] . Nevertheless, this activation of FOXP3 by S implies that S antigens may participate in Treg cell activation. In Step 4, the semiallogeneic blastocyst that has developed from the fertilized egg implants itself on the mesometrial side of the uterus. Guerin et al. [1] describe the generation of effector T cells in response to male ejaculate, and CCL5 may facilitate recruitment of these cells to the uterus [4] . If the TcR (T cell receptors) of effector T cells can recognize blastocyst-derived antigens taken up and presented by Mphs and DCs, local inflammation can be triggered, leading to destruction of the implanting embryo. If Treg cells reactive with these antigens are also present, the reaction is abrogated in what has been called an immunological stalemate, or tolerance [1, 3, 4] . In nonejaculate-exposed pseudopregnant females, transfer of GD 3.5 blastocysts to GD 2.5 pseudopregnant mice may suffice to generate a sufficient Treg response to blastocyst-derived antigens to prevent pregnancy loss. [12] .
EJACULATE BOOSTS PREIMPLANT TREGS IN UTERUS
TGFB is a cytokine that promotes Treg cell generation, has been suggested to derive from a pro-TGFB in seminal plasma, and has been shown to locally recruit predominantly CD4 þ CD8 þ FOXP3 þ cells to the genital tract [1, 12] . In a conventional Treg assay, cells staining with CD4 þ include the CD4 þ 8 þ subset that can potentially react to peptides presented via maternal Class I or Class II MHC. Both MHC and non-MHC antigens are involved in preventing abortion in the CBAxDBA/2 model and in preventing abortions triggered by the nonspecific proinflammatory activator polyIC [16] . This suggests that Tregs, once activated, are able to nonspecifically suppress inflammation within the uterus. Production of CCL19 by epithelial cells, in addition to Mphs and DCs, ensures that Treg cells will be recruited close to the site where inflammation can compromise the success of the embryo. However, the maintenance of Treg function appears to require that DCs present antigens to the abTcR on Treg cells. The exact nature of these antigens in ejaculate remains uncertain, but it would seem that their antigenic determinants (epitopes) must be similar to what the implanting embryo can produce and release.
How Do Treg Cells Do It?
Classical murine Treg cells are
bright is linked to suppressive activity. Several mechanisms of suppression have been described; close contact with the target (e.g., with DCs) is required [1, 17] . Treg cells may act on DCs through a variety of molecules, including cellsurface CTLA4, SLC4A1 (CD223), galectin-1 (LGALS1), NRP1, ENTPD1 (CD39), IL12A (IL-35), soluble FGL2, and IL10 [15] . FGL2 in membrane-bound form can act as an abortogenic prothrombinase, but when released in soluble form, it binds to FccRIIb (FCGR2B) receptors on antigenpresenting cells to nonspecifically suppress T effector cell proliferation [18, 19] . It is therefore quite interesting to note that there are cells that stain for FGL2 around the embryo in the CBAxDBA/2 model on GD 5.5 and 6.5 [20] . FGL2-producing CD8 þ T cells have been found in tolerated allografts [21] , and CD8 þ maternal cells appear to reduce abortion rates up to about GD 6.5 in the CBAxDBA/2 model [2, 11, 22] . Further studies are needed to phenotype the FGL2 þ cells at GD 5.5 and to determine if their number is greater in low-abortion rate CBAxBALB/c matings.
Is It Relevant?
It has been written that the proper study of man is man, but there are many advantages in starting with an animal model such as the mouse. Eventually, one must question the relevancy of the mouse model to humans and to explain this convincingly in the relevance section of one's grant proposal. Taxpayers want to pay for research that will solve human problems, not mouse problems. In humans, activated T cells, increased blood NK cell levels, increased blood NKT cells, and autoimmunity have been linked with implantation failure and recurrent spontaneous abortion of normal karyotype embryos [12, 23] . Maternal T cells (or NKT cells) from women with unexplained recurrent pregnancy failure produce Th1 cytokines in response to trophoblast or sperm antigens [12] . In the mouse, the male ejaculates directly into the uterine lumen, whereas in the human, the ejaculate is restricted to the vagina [12] . Nevertheless, there is an immune reaction in the cervix [1] , and repeated exposure to semen has been shown by Robilliard et al. [24] to significantly decrease the risk of certain pregnancy problems such as preeclampsia where the underlying pathogenesis involves an inhibition of fetal trophoblast migration into decidua and the walls of maternal spiral arteries. For several reasons, this problem is thought to have an immunological basis and an immunological solution through ejaculateinduced maternal tolerance (as shown in the mouse) [14, [24] [25] [26] . Implantation failure and recurrent spontaneous abortion are also now associated with a deficiency of Treg activity in a proportion of affected women [12, [27] [28] [29] . The data provided by Guerin et al. [1] take us a step forward by providing data on mechanisms that can be examined in women with a view to making the Treg response sufficiently effective to prevent implantation, recurrent miscarriages, growth retardation, and/or preeclampsia in those women who have subnormal Treg levels and a subnormal Treg response to paternal antigens in ejaculate.
